title: Efficacy and side effects of intermittent recombinant interferon-alpha 2a in chronic aggressive hepatitis C: with or without initial daily administration.
abstract: To investigate the therapeutic effect and incidence of side effects of recombinant interferon-alpha 2a (IFN-alpha) in chronic aggressive hepatitis C under stratification by administration mode, a study was conducted by assigning patients to either group A (daily consecutive administration of 9 million units (MU) IFN-alpha for 2 weeks and, thereafter, 3 MU intermittently 3 times weekly for 22 weeks) or group B (exclusively intermittent administration; 9 MU IFN-alpha twice weekly or 6 MU IFN-alpha thrice weekly for 24 weeks). The 28 patients in group A received IFN-alpha for 24 weeks up to a total dose of 324 MU and the 53 patients in group B received the same for 24 weeks up to a total dose of 432 MU. When recovery was defined as the absence of hepatitis C virus (HCV)-RNA 6 months after the completion of treatment, the rate of recovery for group A was 32.1% and that for group B was 37.7%, the latter being higher but without significance. Side effects in groups A and B consisted of leucopenia occupying 14.3 and 7.5%, respectively, and thrombocytopenia occupying 42.9 and 11.3%, respectively; group B exhibited lower values for both side effects. No difference was detected between these groups in other side effects, including pyrexia, generalized malaise, arthralgia or psilosis. Intermittent administration from the outset permitted shortened duration of hospitalization and earlier rehabilitation. Intermittent administration of INF-alpha is required when treating patients with chronic hepatitis C showing lower leucocyte or platelet counts.
authors.affiliation: Second Department of Internal Medicine, Wakayama Medical University, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Itoh
authors.forename: H
authors.initials: H
authors.lastname: Nakata
authors.forename: Y
authors.initials: Y
authors.lastname: Yokoya
authors.forename: S
authors.initials: S
authors.lastname: Nakashima
authors.forename: T
authors.initials: T
authors.lastname: Yamanishi
authors.forename: T
authors.initials: T
authors.lastname: Hara
authors.forename: J
authors.initials: J
authors.lastname: Kawai
authors.forename: H
authors.initials: H
authors.lastname: Miyamoto
authors.forename: K
authors.initials: K
authors.lastname: Higashi
authors.forename: S
authors.initials: S
authors.lastname: Nishioka
mesh_terms: D002908:Chronic Disease; D004334:Drug Administration Schedule; D005260:Female; D006526:Hepatitis C / Q000628:therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins